ARUXF
Acrux Ltd.OTCPK - Current
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Nov. 24, 2010, 8:26 AM

    The FDA approves Axiron, Eli Lilly's (LLY) topical solution for testosterone replacement therapy in men. The U.S. testosterone market, estimated at $1B, is set to grow 20% annually. Acrux (ARUXF.PK), Lilly's Australian partner on the drug, rose 9.1% in Aussie trading.

    | Nov. 24, 2010, 8:26 AM